(Q39753695)

14 September 2017

Selective inhibitor of proteasome's caspase-like sites sensitizes cells to specific inhibition of chymotrypsin-like sites (English)

1 reference

14 September 2017

Sondra L Downey

3

0 references

Martijn Verdoes

object named as

Martijn Verdoes

6

0 references

Dennis L Wright

object named as

Dennis L Wright

11

0 references

Herman S Overkleeft

object named as

Herman S Overkleeft

12

0 references

author name string

Matthew Britton

1

1 reference

14 September 2017

Marcella M Lucas

2

1 reference

14 September 2017

Michael Screen

4

1 reference

14 September 2017

Alexandre A Pletnev

5

1 reference

14 September 2017

Robert A Tokhunts

7

1 reference

14 September 2017

Omar Amir

8

1 reference

14 September 2017

Ayrton L Goddard

9

1 reference

14 September 2017

Philip M Pelphrey

10

1 reference

14 September 2017

Alexei F Kisselev

13

1 reference

14 September 2017

1 December 2009

1 reference

14 September 2017

Chemistry and Biology

1 reference

14 September 2017

16

1 reference

14 September 2017

12

1 reference

14 September 2017

1278-1289

1 reference

Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2807417

Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2807417

CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2807417

LMP2-specific inhibitors: chemical genetic tools for proteasome biology

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2807417

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2807417

Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2807417

Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2807417

Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2807417

The proteasome: a suitable antineoplastic target

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2807417

A phase 2 study of bortezomib in relapsed, refractory myeloma

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2807417

The caspase-like sites of proteasomes, their substrate specificity, new inhibitors and substrates, and allosteric interactions with the trypsin-like sites.

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2807417

Proteasome inhibitors: from research tools to drug candidates

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2807417

26S proteasomes and immunoproteasomes produce mainly N-extended versions of an antigenic peptide

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2807417

The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2807417

The catalytic sites of 20S proteasomes and their role in subunit maturation: a mutational and crystallographic study

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2807417

Proteasome inhibitors: a novel class of potent and effective antitumor agents.

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2807417

Contribution of proteasomal beta-subunits to the cleavage of peptide substrates analyzed with yeast mutants

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2807417

The active sites of the eukaryotic 20 S proteasome and their involvement in subunit precursor processing

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2807417

Identification of the yeast 20S proteasome catalytic centers and subunit interactions required for active-site formation

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2807417

Structure of 20S proteasome from yeast at 2.4 A resolution

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2807417

Autocatalytic subunit processing couples active site formation in the 20S proteasome to completion of assembly

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2807417

Cell-based bioluminescent assays for all three proteasome activities in a homogeneous format.

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2807417

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2807417

Binding of hydrophobic peptides to several non-catalytic sites promotes peptide hydrolysis by all active sites of 20 S proteasomes. Evidence for peptide-induced channel opening in the alpha-rings

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2807417

Redundancy of mammalian proteasome beta subunit function during endoplasmic reticulum associated degradation

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2807417

Towards subunit-specific proteasome inhibitors: synthesis and evaluation of peptide alpha',beta'-epoxyketones.

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2807417

A cell-permeable inhibitor and activity-based probe for the caspase-like activity of the proteasome

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2807417

Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate

2 December 2018

1 reference

12 December 2020

Selective proteasome inhibitors: modulators of antigen presentation?

1 reference

12 December 2020

Monitoring activity and inhibition of 26S proteasomes with fluorogenic peptide substrates

1 reference

12 December 2020

Structure-based design of derivatives of tyropeptin A as the potent and selective inhibitors of mammalian 20S proteasome

1 reference

12 December 2020

Proteasome active sites allosterically regulate each other, suggesting a cyclical bite-chew mechanism for protein breakdown

1 reference

12 December 2020

10.1016/J.CHEMBIOL.2009.11.015

Identifiers

DOI

1 reference

14 September 2017

1 reference

14 September 2017

PubMed publication ID

20064438

1 reference